Trial Profile
Antibody Persistence in 11 to 13-year-old Children Previously Vaccinated at 6 Years Old With Either REVAXIS or DT Polio, and Immune Response to a Booster Dose of TETRAVAC-ACELLULAIRE
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2017
Price :
$35
*
At a glance
- Drugs DTaP poliovirus vaccine (Primary) ; DT-poliovirus vaccine
- Indications Diphtheria; Pertussis; Poliomyelitis; Tetanus
- Focus Pharmacodynamics
- Sponsors Sanofi Pasteur; sanofi pasteur MSD
- 03 Jul 2012 Status for the extension trial changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov (Extension trial: NCT01546909).
- 06 Jun 2012 Planned end date for the extension trial is Nov 2012 as reported by ClinicalTrials.gov (Extension trial: NCT01546909).
- 06 Jun 2012 Trial status for the extension trial is recruiting as reported by ClinicalTrials.gov (Extension trial: NCT01546909).